Swiss recommendations for the management of genital herpes and herpes simplex virus infection of the neonate. by Swiss Herpes Management Forum
Swiss recommendations for the management
of genital herpes and herpes simplex virus
infection of the neonate
Swiss Herpes Management Forum1
This document is aimed at practising physi-
cians. The recommendations have been developed
on the basis of directives [1, 2] recently published
in Europe and the United States but take into con-
sideration recent developments in virology, clini-
cal practice and treatment of herpes infections as
well as special features of the Swiss Pharma-
copoeia. The quality of the evidence and of the rec-
ommendations has been weighted and coded in ac-
cordance with the established standards (table 1).
Genital herpes is a viral disease acquired by
mucocutaneous contact. The primary infection
has various clinical forms and remains asympto-
matic in the majority of cases [3]. If symptomatic,
primary infection manifests itself with local and
frequently systemic signs [4]. Both herpes simplex
virus types (HSV-1 and HSV-2) can cause primary
genital infection, whereby the proportion of HSV-
1 is increasing in Europe [5, 6]. These viruses la-
tently infect the sensory sacral ganglia, where they
reactivate with or without inducing symptoms.
The frequency of clinical recurrence varies be-
tween patients and diminishes with the years after
primary infection [7]. In the genital area HSV-2
reactivates much more frequently than HSV-1.
The prevalence of HSV-1 and HSV-2 can be de-
termined by type-specific serological tests. About
70% of adult Swiss are infected with HSV-1, about
20% with HSV-2 [8]. Of 25 Swiss adults, one has
a diagnosed, recurrent genital herpes, three have
an undiagnosed genital herpes and one presents
with a truly asymptomatic infection.
Genital herpes is being recognised as a med-
ical problem of increasing importance. Diagnosis
and management are complex. The present rec-
ommendations have been established by a multi-
disciplinary panel of specialists and endorsed by all
Swiss medical societies involved in the medical
care of such patients (Appendix). The aim is to
improve the care of affected patients, to reduce
horizontal and vertical transmission and to dimin-
ish the psychosocial burden.
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Table 1
Evidence and recommendations.
Evidence level Study type
I Controlled and randomised study (or systematic examination of such studies)
II Controlled, but not randomised study
III Prospective cohort study
IV Retrospective cohort study or case control study
V Case studies, expert’s opinion
Recommendation level Evidence
A Good evidence to support the recommendation (generally based on Evidence Level I)
B Faire evidence to support the recommendation (generally based on Evidence Level II or III)
C Inadequate evidence; recommendation may be made on other grounds
D Fair evidence against the recommendation (generally based on Evidence Level II or III)
E Good evidence against the recommendation (generally based on Evidence Level I)
A risk of transmission exists even in the ab-
sence of symptoms. Most horizontal (between
partners) or vertical (mother-to-child) transmis-
sions take place during asymptomatic infection [9,
10] (III). The risk of transmission from man to
woman is approximately five times higher than vice
versa (III). Latex condoms reduce the risk of in-
fection (C). In one study [11] (I) the use of latex
condoms in at least 25% of the sexual contacts re-
duced the risk of transmission from man to
woman. The efficacy of condoms in preventing
transmission from women to men has not been
assessed. Suppressive treatment with valaciclovir
reduces transmission of HSV-2 between serodis-
cordant partners by 50% [12] (I). The increasing
prevalence of orogenital sexual practices explains
the increase in the frequency of HSV-1-related ini-
tial episodes of genital herpes in the USA [13] (III).
Prior infection with HSV-1 seems not to protect
against infection with HSV-2 but does diminish
the probability of symptomatic herpes disease [3].
Genital herpes promotes transmission of HIV
in HSV-2 seropositive persons [14] (III). Conse-
quently, measures which prevent the transmission
of HSV-2 contribute indirectly to the prevention
of transmission of HIV (B).
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Transmission
Diagnosis
Case history and presentations
Primary infection
In more than half of patients primary infection
goes unnoticed [3]. If symptoms are present, pri-
mary genital herpes occurs 3 days to 2 weeks after
exposure from an infected sexual partner and man-
ifests as a group of painful vesicles that progress to
ulcers over several days. Primary disease is typi-
cally severe with large multiple ulcerations and
tender inguinal lymphadenopathy. Over one-half
of the patients suffer from constitutional com-
plaints. Up to 20% of patients have dysuria, some
develop frank urinary retention and a minority de-
velop aseptic meningitis [15]. Lesions completely
resolve after 3 weeks. An identical clinical syn-
drome is produced by both HSV-types.
Non primary episodes or initial infections in
the presence of prior antibodies to HSV result in
milder episodes with lower frequency of constitu-
tional symptoms. In practice, clinical distinction of
primary infection from initial infection may be im-
possible.
Recurrent genital herpes
HSV can reactivate in the genital tract either
asymptomatically or symptomatically. Classical
symptoms are grouped vesicles with progression to
ulceration and crusting. Lesions are typically fewer
in number and smaller than in primary disease.
Constitutional symptoms are rare [16]. Up to 89%
of patients with a symptomatic first episode due to
HSV-2 experience symptomatic recurrences of
variable frequency and severity [17] (III). Recur-
rence frequency in the genital region is much
greater for HSV-2 than HSV-1 [18] (III). Recur-
rence is often heralded by prodromal symptoms of
burning or tingling at the site of the outbreak or
by neuralgic pain.
However, in many patients the lesions and
their localisation are less typical and may not be
identified as genital herpes unless a careful history
and appropriate diagnostic tests are performed [16,
19, 20] (III). If patients who deny having genital
herpes but have a serologically detectable HSV-2
infection are informed in detail about their condi-
tion, half of them will subsequently recognise her-
petic lesions [20] (III).
Clinical manifestations Type of infecting HSV HSV antibodies Classification of infection
Symptoms recognised as HSV-2 None Primary HSV-2
genital herpes: First episode HSV-1 None Primary HSV-1
HSV-2 HSV-2 Non primary HSV-2
HSV-1 HSV-1 Non primary HSV-1
HSV-2 HSV-1 Initial HSV-2
Symptoms recognised as HSV-2 HSV-2 with or without HSV-1 Recurrent HSV-2
genital herpes: Recurrent herpes HSV-1 HSV-1 with or without HSV-2 Recurrent HSV-1
Absence of episode of genital herpes HSV-2 HSV-2 with or without HSV-1 Asymptomatic shedding
(theoretically also none) of HSV-2
HSV-1 HSV-1 with or without HSV-2 Asymptomatic shedding
(theoretically also none) of HSV-1
Symptoms not recognised HSV-2 HSV-2 with or without HSV-1 Unrecognised symptomatic 
as genital herpes (theoretically also none) genital HSV-2
HSV-1 HSV-1 with or without HSV-2 Unrecognised symptomatic 
(theoretically also none) genital HSV-1
Table 2
Different classifica-
tions of genital
herpes infections.
So-called atypical localisations (buttocks, anal
or thigh region) are relatively common (up to 61%
in women) and sometimes accompanied by neu-
ralgia [21] (IV). Laboratory tests to confirm herpes
infection in such cases are therefore justified (C).
Atypical presentations become more common
with increasing prevalence of impaired immunity,
eg, after transplantation or HIV infection, where
chronic and more extensive lesions are seen.
Different classifications of genital herpes are
listed in table 2.
Detection of infections with herpes simplex
viruses
Herpes infection may be identified directly by
detection of the virus or one of its components
(table 3), or indirectly by assaying for specific
serum antibodies to the viruses [22–24].
Virus detection
There are many methods of detection. They
are all variants of one of the three basic methods:
– virus culture
– virus antigen detection with specific antibod-
ies (enzyme immunoassay or immunofluores-
cence)
– identification of the sequences of the viral
genome after enzymatic amplification (poly-
merase chain reaction, PCR) their character-
istics and use are presented in table 3.
Antibody detection 
HSV-1 or HSV-2 infection can be diagnosed
in the absence of lesions in the patient or sexual
partner by detection of type-specific IgG against
the glycoprotein G of HSV-1 (gG-1) or the glyco-
protein G of HSV-2 (gG-2). In commercially
available products which can distinguish type-spe-
cific IgG, recombinant glycoproteins are predom-
inantly used (see lists published by the Federal Of-
fice for Public Health and Swissmedic: www.bag.
admin.ch/md/ivd/list_h.pdf) 
Whilst significance is given to the detection of
type-specific IgG in sexual partners and STD clin-
ics it must be remembered that there are certain
limits to the usefulness of type-specific serology. A
primary infection cannot automatically be inferred
from a negative serological result for a type (HSV-
1 or HSV-2) because:
– A type-specific immune response can take
weeks to months to fully develop following
primary infection. The IgG response to gG-2
takes 8 weeks on average. The gG-1 response
takes longer. Antiviral therapy can further
delay seroconversion.
– IgG against gG-1 and gG-2 can gradually dis-
appear. Thus antibodies may be absent in a la-
tently infected patient who has not been re-ex-
posed for a long time or has not undergone a
reactivation of the latent virus infection [25].
– In very rare cases the detectable antibody re-
sponse is not directed against the glycoprotein
(gG-2) used in the tests.
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Method Tissue sampled Sensitivity Specificity Advantages Disadvantages
[22–24]
Virus detection Skin/mucosal lesions >90% >95% – simplicity of sampling – only available in 
by cell culture (stage) 80% – typing and resistance specialised laboratories
– vesicular content 40% phenotype determination – virus transport medium 
– ulcers <40% possible necessary
– scabs 40–80% – transport must be rapid,
– mucosa without lesions unknown cooled, protected from light 
Biopsies – result available after 
Conjunctival smear/corneal scrapings 2–7 days
Neonates – not suitable for 
cerebrospinal fluid (CSF)
– arrangement with laboratory
necessary
Antigen detection Smears from lesions, vesicular 41–80% 80% – simplicity of sampling – suitable only for 
by ELISA* content with base of vesicle – rapid (<4 h possible) fresh vesicles
– typing possible
Immunfluorescence Smears, tissue sections, 41–70% >95% – rapid (<4 h possible) – suitable only for 
(detection of smears from base of vesicle – typing possible fresh vesicles
infected cells) – available only in 
specialised laboratories
– technically demanding
– not standardised
Polymerase chain Cerebrospinal fluid 98% >95% – most sensitive method – available only in 
reaction (PCR) Aqueous or vitreous ** >99% – result within 24 h specialised laboratories
humour – no special measures – not standardised
Skin lesions, vesicular needed for transport – risk of contamination
content or mucosa without – applicable until a – not validated for all samples
lesions few days after start of therapy
– typing possible
– resistance genotyping possible
– method of choice for CSF 
* ELISA: Enzyme-Linked Immunosorbent Assay **about 20% more sensitive than cell culture
Table 3
Virus detection.
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Therapy of genital herpes  
Antiviral drugs are central to the therapy of
genital herpes. The physician should take into ac-
count the patient (immunocompetent, immuno-
compromised, pregnant, newborn), the stage of
the disease (primary, recurrent), and the objective
of the treatment (therapeutic-episodic, prophylac-
tic-suppressive).
Systemic antiviral drugs diminish the signs and
symptoms of an episode of primary genital herpes
and also – to a lesser degree – of the recurrences.
Used as suppressive therapy they lower the fre-
quency of recurrences significantly. They do not
eradicate the latent infection nor do they affect the
frequency and severity of the recurrences after dis-
continuation of the suppressive treatment. Ran-
domised studies indicate that three drugs have a
similar clinical effect on genital herpes: aciclo-
vir, valaciclovir and famciclovir. Valaciclovir, the
L-valine ester of aciclovir, has a significantly 
better bioavailability than aciclovir. Famciclovir, 
a prodrug ester of penciclovir, also has a high
bioavailability.
Topical treatment with antiviral drugs is not of
demonstrable clinical benefit [26] (I) and is there-
fore not recommended (E).
Therapy of first episode 
The usually severe symptoms warrant antivi-
ral treatment. It should be started as early as pos-
sible without waiting for the laboratory results (A).
The symptoms subside almost a week earlier if
treatment is started within 5 days of the outbreak
of symptoms [27–30]. The recommended thera-
pies are listed in table 4. The valaciclovir dosage of
1000 mg twice daily used in the USA is based on
the results of the study by Fife et al. [30] (A). Valaci-
clovir dosed at 500 mg twice daily produces a
higher plasma concentration than aciclovir 200 mg
five times daily [31] and the dosage of 500 mg of
valaciclovir twice daily is preferred in Europe (A).
The clinical efficacy of 500 mg twice daily was con-
firmed in a controlled study [32] (I). If the clinical
picture is protracted with persistent lesions, par-
ticularly in immunodeficient patients, treatment
may be maintained for at least 14 days. Aciclovir,
valaciclovir and famciclovir appear to be of similar
efficacy, so the choice is based on tolerance, com-
pliance and cost. The treatment of the first episode
has no influence on the recurrence rate [33–35] (I).
The following complications require hospital-
isation: sphincter disorders with urine retention,
meningitis, severe general symptoms, and inabil-
ity to take oral medicines. In the case of urine re-
tention a catheter may be left in situ for a few days,
a suprapubic drainage being preferred (C).
Analgesics are recommended. Local anaes-
thetics should be used reluctantly to avoid sensiti-
sation. Topical antiseptic and anti-inflammatory
treatment with iodine-containing or astringent so-
lutions (tannins) applied by bathing or with gauze
pads is recommended (C).
Therapy of recurrences 
Depending on the severity of the recurrences,
episodic or suppressive oral antiviral therapy or
symptomatic local therapy will be indicated. The
type of treatment is chosen after discussing each
option with the patient. An episodic treatment for
2–5 days (table 4), which is started by the patient
within 24 hours of symptom onset, can shorten the
duration of an episode by 1 or 2 days [29, 36–42].
Suppressive treatment can prevent about 80% of
the recurrences and has a much greater effect on
the morbidity associated with genital herpes than
episodic treatment [43] (I).
Episodic tratment
Because the medication needs to be started
without delay when symptoms occur, the patient
must be given an antiviral starter pack or a pre-
scription with appropriate directions (table 4)
[37–42] (C).
Suppressive treatment 
In patients with frequent recurrences (>6 per
year) suppressive treatment reduces the frequency
of recurrence by 70 to 80% [44] (I). The safety and
efficacy of suppressive treatment have been ob-
served for a period of more than 10 years for aci-
clovir [45] and for a period of more than one year
for valaciclovir and famciclovir [29, 44, 46–48].
Valaciclovir 250 mg twice daily is slightly more ef-
fective than 500 mg once daily and is therefore rec-
ommended for patients with more than 10 recur-
rences per year [44] (A). The suppressive treatment
improves the quality of life [49] (I). The frequency
of recurrences decreases with the number of years
since the first attack [7]. This suggests that sup-
pressive treatment should be discontinued for a
while after 6–12 months (ie, wait for at least two
recurrences) so as to estimate the residual recur-
rence frequency [50] (B). Suppressive treatment
can be resumed if frequent or stressful recurrences
continue to occur. It causes neither appreciable
side effects nor selection of resistant strains [51]
(IV). 
The suppressive treatment with valaciclovir
taken by persons with recurrences had another
major impact: the reduction of genital HSV-2
transmission in serodiscordant monogamous cou-
ples. Once daily 500 mg valaciclovir reduced by
50% the transmission of HSV-2 and by 75% clin-
ically symptomatic HSV-2 infections [12] (I).
Treatment in immunocompromised patients  
Chronic or severe lesions are observed in the
immunocompromised and, in particular, in ad-
vanced HIV infection. Episodic or suppressive
treatment is generally recommended for these pa-
tients [29] (B). Intravenous administration may be
needed in severe cases (eg, visceral dissemination)
or in case of inability to take oral drugs (table 4).
The risk of selection of resistant strains increases
with the degree of immunosuppression and the
number of antiviral courses. If the lesions no
longer respond to the standard treatment an expe-
rienced specialist should be consulted (C). 
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First episode Recurrent episodes
Immunocompetent persons
Episodic treatment Regimens licensed in Switzerland: Regimens licensed in Switzerland:
Aciclovir oral 200 mg five times daily for 5–10 d [27, 34] (A) Aciclovir oral 200 mg five times daily for 5 d [38, 39] (A)
Valaciclovir 500 mg twice daily for 5–10 d (A) Valaciclovir 500 mg twice daily for 3–5 d [37, 42] (A)
Famciclovir 250 mg thrice daily for 5–10 d (C*) Famciclovir 125 mg twice daily for 5 d [40] (A)
Aciclovir iv 5 mg/kg thrice daily for 5 d [28, 35] (A) Other regimens:
Other regimens: Aciclovir oral 400 mg thrice daily for 5 d (C)
Aciclovir oral 400 mg thrice daily for 7–10 d (C) Aciclovir oral 800 mg thrice daily for 2 d [41] (A)
Valaciclovir 1000 mg twice daily for 7–10 d [30] (A)
Suppressive treatment – Aciclovir oral 400 mg twice daily [52, 53] (A)
(Recommended if >6 Valaciclovir 250 mg twice daily 
recurrences/year or serious (>10 recurrences/year) or 
effect on quality of life) 500 mg once daily (<10 recurrences/year) [37] (A)
Famciclovir 250 mg twice daily [47, 48] (A)
Immunocompromised persons
Episodic treatment Consultation with specialist(s) (C) Aciclovir iv 5 mg/kg thrice daily [54] (A)
Aciclovir 400 mg five times daily [55] (A)
Valaciclovir 1000 mg twice daily [56] (C)
Famciclovir 500 mg twice daily [57] (A, AIDS-patients)
Suppressive treatment – Aciclovir 400–800 mg twice or thrice daily [54]
Valaciclovir 500 mg twice daily (A*)
Famciclovir 500 mg twice daily [58] (A)
Symptomatic treatment Analgesics, antiseptic and local anti-inflammatory treatment (C) Analgesics, antiseptic and local anti-inflammatory 
treatment (C)
Pregnancy
Episodic treatment Aciclovir oral 200 mg five times daily for 10 d Aciclovir oral 200 mg five times daily for 5 d
Valaciclovir 500 mg twice daily for 10 d** Valaciclovir 500 mg twice daily for 5 d
Suppressive treatment Aciclovir oral 400 mg thrice daily Aciclovir oral 400 mg thrice daily
(from week 36 until delivery) Valaciclovir 250 mg twice daily** Valaciclovir 250 mg twice daily**
*   published as Abstract, cited in [29]
** Aciclovir pregnancy registry and valaciclovir pregnancy registry, 1 June 1984 – 30 April 1999
Table 4
Treatment of 
genital herpes.
Information and advice for the patient 
Information and counselling are integral to
the treatment of genital herpes and have two ob-
jectives: to help the patient to cope with the dis-
ease and to prevent sexual and perinatal transmis-
sion [59]. In general, comprehensive information
and advice cannot be given within a single consul-
tation. Many patients use additional sources of
information such as leaflets and internet sites (eg,
www.herpesalliance.org , www.herpesnet.ch ).
The psychosocial burden of genital herpes
should not be underestimated. It is often perceived
as a stigmatising disease and diminishes the qual-
ity of life. Counselling helps the patient to better
understand the negative feelings related to recur-
rent herpes [60] (B). The patient should also be in-
formed that HSV-2 does not play a causative role
in the pathogenesis of cervix carcinoma (A).
The points to be discussed with patients are
presented in table 5 (Patient counselling checklist).
Management of the partner 
Sexual partners should also be given advice.
Symptomatic partners should be managed in the
same way as the index patient. Asymptomatic part-
ners should be questioned regarding genital lesions
and be educated to recognise herpes lesions. Type-
specific serological testing should be offered (C).
Vertical transmission 
Both HSV-2 and HSV-1 can be transmitted
from the mother to the neonate during parturition
and cause severe infections. In Switzerland the in-
cidence of neonatal herpes infection is apparently
low according to an ongoing nation-wide surveil-
lance study [61].
The risk of transmission depends on the char-
acter of the current episode (primary infection car-
ries a much greater risk than recurrence) and the
virus type (HSV-1 > HSV-2). Thus in cases where
viruses are positively identified at delivery it may
vary between 30% in primary infections and <1%
in recurrent infections [62, 63]. The risk of trans-
mission is reduced following caesarean delivery
(OR 0.14 95%-CI 0.02–1.08) [62] (III).
Estimation of the risk for the neonate 
The clinical distinction between primary in-
fection, initial infection with the other HSV type
and reactivation during pregnancy is not possible.
However, it would be of utmost importance for the
assessment of the risk to the neonate (III). A first
manifestation of genital herpes during pregnancy
is in most cases not a primary infection [64]. Con-
versely, most primary infections are not sympto-
matic [63]. An episode that appears clinically to be
a recurrence may well be an initial infection with
the other serotype and thus present a considerably
higher neonatal risk [62]. On the basis of these data
it would not appear logical to manage first presen-
tation and recurrent episodes of genital herpes dif-
ferently during pregnancy. This changes if the type
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Genital herpes during pregnancy
Topic to discuss Approach
Natural course and epidemiology
Course and forms Explain recurrence potential, asymptomatic virus secretion, and risk of transmission
of the disease
Mention that genital herpes can be caused by HSV-2 or by HSV-1
Point out that one in six people is affected worldwide
Emphasise that about 80% of the infections are not recognised because the symptoms are minimal or absent
Information Motivate the patient to tell present and future sexual partners about his/her infection status
to sex partners
Sexual partners of infected persons should be told that they may be infected even in the absence of symptoms
A type-specific serological investigation can be helpful for guidance as to the necessary precautions
Asymptomatic virus Explain that asymptomatic secretion is responsible for transmission in most cases
secretion
It occurs more frequently in the first year after the primary infection, in immunocompromised patients 
and in patients with frequent recurrences (>12/year)
Mention that HSV-2 is shed asymptomatically from the genitalia much more frequently than HSV-1
Contact Explain that transmission occurs genitally by skin contact (even in the absence of penetration, 
transmission eg, during “petting”)
Transmission also occurs orogenitally and all body regions can be affected as a result of inadvertent 
(auto)inoculation
Emphasise that virus shedding is practically certain if prodromi or lesions occur so sexual contact with uninfected
partners should be forgone at these times
Condom use Explain that latex condoms can reduce the risk of infection from man to woman
Neonatal herpes Explain that herpes neonatorum is the most serious, albeit rare, complication
Pregnant women or women of childbearing age who are infected with HSV-2 must inform the obstetrician/
midwife and paediatrician
Pregnant women not infected with HSV-2 must be made aware of the danger of sexual contacts
(genital and orogenital) with an infected partner during pregnancy (especially in the last trimester)
Atypical symptoms Asymptomatic persons diagnosed by type-specific serology as having an HSV-2 infection must be counselled 
and the possible skin manifestations (including atypical forms) be explained
Therapeutic options
Options Explain the options (episodic antiviral therapy, suppressive therapy, symptomatic local therapy)
Breakthrough Explain that recurrences may occur despite suppressive therapy and that they usually last only a few days
infections
When breakthrough occurs the drug dose is temporarily increased to that given for episodic treatment (Table 4)
Suppressive Emphasise that suppressive therapy does not alter the natural course of the infection and that recurrences are 
treatment to be expected after it has been discontinued
Although the frequency of recurrences usually decreases over time at a rate that varies from patient to patient, 
some patients will experience frequent recurrences after stopping suppressive treatment, in which case the 
suppressive treatment can be resumed
Effect on virus Point out that suppressive treatment diminishes the shedding of virus significantly [12] (I) and reduces the risk 
shedding of virus transmission by 50% [12] (I)
Tolerance Reassure the patient that adverse effects of suppressive treatment are extremely rare and that no problems
of resistance have been observed in immunocompetent patients
Table 5
Patient counselling
checklist.
of infection can be characterised by virus typing
and determination of the type-specific antibodies.
Neither serological nor virological (culture or
PCR) screening of the mother before delivery per-
mit reliable identification of neonates at risk of
neonatal herpes infection [62] (III). Therefore
such investigation cannot routinely be recom-
mended (D). The value of serological screening
early in pregnancy to identify women at risk for
primary infection is under investigation.
Management of pregnant women with a first
or recurrent episode of genital herpes 
Treatment of clinical episodes 
Pregnant women with a first clinical episode
or a recurrence may be treated with aciclovir or
valaciclovir at the recommended dosages (table 4).
An excess risk for the foetus has not been associ-
ated with these treatments [65, 66].
Suppressive treatment 
Randomised studies have shown that suppres-
sive treatment from the 36th week of pregnancy
until delivery reduces the frequency of clinical
manifestation and virus shedding at the time of de-
livery and, in many cases, caesarean section can be
avoided [67–70] (I) (A).
Route of delivery 
A history of genital herpes in the absence of
genital symptoms (active lesions or prodromal pain
or burning) at the beginning of delivery should not
be taken as an indication for an elective caesarean
section [70] (E). If clinical herpes lesions, positive
virus detection tests, or both are present at the time
of delivery, then a caesarean section is an effective
preventive measure [62] (III) and therefore indi-
cated (B). At membrane rupture, if it may be as-
sumed that the foetal lungs are mature, a caesarean
section should be performed as quickly as possible
and no more than 4–6 hours later [69] (B).
In case of immature lungs there is no estab-
lished basis for the decision. Continuing the preg-
nancy carries a small residual risk of a manifest
foetal/neonatal herpes infection despite maternal
antiviral therapy (with or without induction of
lung maturation with corticosteroids). This must
be weighed against the risk (which depends pri-
marily on the gestational age) of immediate deliv-
ery by caesarean section [69]. The risk of expectant
management of pregnant women with recurrent
genital herpes and preterm premature rupture of
membranes appears to be small [70] (IV) (B). In
these complex cases the immediate transfer to a
specialist centre is recommended (C).
As long as the membranes are intact and con-
tractions have not started an episode of recurrent
genital herpes in the weeks before the expected de-
livery date should not be taken as an indication for
an elective caesarean section [70] (D). It must be
remembered that even in the 37th and 38th weeks
of pregnancy there is still a substantial risk of
neonatal respiratory distress syndrome which is
sharply increased by delivery by elective caesarean
section [71] (III).
After a clinical recurrence during pregnancy,
vaginal delivery is possible as soon and as long as
no clinical lesions are present. However, if in the
third trimester a primary or an initial genital in-
fection has been established or seems highly prob-
able, the optimal way of proceeding is not well de-
fined. Most guidelines propose caesarean section
for all women developing a primary clinical infec-
tion within 4–6 weeks of delivery [1, 72–76] (IV)
(C). But some experts think that the foetus may be
at risk from vaginal delivery until the appearance
of type-specific IgG which may take 8–12 weeks
[77] (C).
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Neonatal herpes simplex infection 
Clinical manifestations 
Neonatal herpes infections appear in three
clinical forms. The most common (50% of cases)
and mildest form remains localised to the skin
and/or eyes and mouth. The form predominantly
involving the CNS, neonatal encephalitis (33%),
manifests as lethargy and seizures and, in many
cases, leads to late sequelae. The disseminated
form (17%) has high lethality and is associated
with hepatitis, pneumonia, disseminated intravas-
cular coagulation and shock [78].
At diagnosis symptoms are found with the fol-
lowing frequencies: skin vesicles 68%, fever 39%,
lethargy 38%, seizures 27%, conjunctivitis 19%,
pneumonia 13%, disseminated intravascular coag-
ulation 11%.
Symptoms may occasionally be present at
birth, but occur in 60% later than 5 days after
birth, and sometimes even present after 4–6 weeks
of life [79] (III).
Diagnostic procedures 
Procedures in cases with known perinatal 
HSV exposure 
In case of manifest genital herpes or known
maternal virus shedding at the time of delivery it
is advisable to cultivate swabs from the neonate’s
conjunctiva, oropharynx and rectum. In order to
demonstrate transmission (and not merely con-
tamination) the swabs should be taken when the
neonate is 24–48 hours old [69] (C).
The neonate must be observed carefully and
long enough (to age 4–6 weeks) for the possible
onset of symptoms of a neonatal herpes infection.
The parents must be instructed accordingly when
the baby is discharged from hospital (B).
Procedures in cases with suspected symptoms of herpes 
Since most neonatal herpes infections occur
where the mother has no history of genital herpes
[63], an HSV infection must be suspected imme-
diately if the neonate exhibits suspicious symptoms
(B). However, one third of neonates with herpes
infection show no characteristic skin lesions and
thus present a particular diagnostic challenge [79].
The possibility of neonatal herpes infection
must be especially considered in case of:
– characteristic skin or mucosal lesions
– conjunctivitis, particularly if there is injection
of the conjunctiva, bulbi, or keratitis
– seizures and/or lethargy without any other ex-
planation
– fever or other systemic symptoms without any
other explanation.
In suspected cases of neonatal HSV infection
the following examinations must be performed
[62] (C):
– cultures of vesicular, conjunctival, oropharyn-
geal, stool/rectal swabs, urine and blood
– lumbar puncture with HSV-PCR (CSF cul-
tures are less sensitive)
– routine laboratory tests including transami-
nases and coagulation tests
– cerebral imaging and/or ophthalmological
examination if indicated.
Therapy and prognosis 
Although high-dose therapy with intravenous
aciclovir for a sufficient length of time has been
proven to be effective [78] (II) neonatal herpes in-
fection is still associated with high residual lethal-
ity and morbidity. Whilst the localised form almost
always heals without sequelae, the CNS form has
a lethality of 6% and permanent late sequelae are
seen in 69% of cases. The disseminated infection
takes a lethal course in 31% and has late sequelae
in 17% of cases [78]. The point in time at which
treatment is started is crucial for prognosis (III).
In order to achieve the best possible treatment
outcomes the diagnostic specimens described in
the preceding chapter must be taken, and intra-
venous therapy with aciclovir 60 mg/kg/d in three
doses started, as soon as there is a clinical suspicion
of neonatal herpes infection (A). If the virological
test results are negative treatment may be discon-
tinued. Localised HSV infections are treated for
14 days and CNS forms or disseminated infection
for 21 days [78] (B). If the eyes are involved addi-
tional topical antiviral therapy must be adminis-
tered.
Cutaneous recurrences may occur for some
time after a neonatal herpes infection. The role of
suppressive therapy for such cases has yet to be elu-
cidated. In cases of herpes infections of the eyes an
ophthalmological examination should be carried
out 2–3 weeks after discontinuing therapy in order
to rule out keratitis.
Since there is no proven basis for pre-emptive
aciclovir therapy for asymptomatic neonates of
mothers with genital herpes it cannot be recom-
mended [69] (D).
Preventive measures 
Neonates with a confirmed or suspected HSV
infection should be isolated and care be taken to
avoid direct contact with skin and mucosal lesions
as well as excretions and body fluids.
Herpes lesions on the lips, fingers or nipples
of the mother or other individuals who have direct
contact with neonates may present a risk, albeit
low, of nosocomial transmission to other neonates.
The mother, the father, visitors and medical staff
on the rooming-in ward must be informed and take
the necessary precautionary measures (sealed
cover of the lesions to prevent direct contact with
the skin or mucosa of the neonate). Medical staff
with oral herpes simplex who observe these pre-
cautions need not be suspended from caring for
neonates [69] (B).
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Ophthalmology 
All patients with eye infections should be re-
ferred for ophthalmological examination on ac-
count of the high risk of complications of even
“simple” epithelial herpes infections of the cornea
and of an extremely high risk of serious permanent
impairments of vision if the deeper layers of tissue
are implicated.
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